The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

11 hours ago · Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $73.71, a high estimate of $90.00, and a low estimate of $63.00.

CouponFollow Extension

$73.71
OFF

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

1 day from now

11 hours ago · Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $73.71, a high estimate of $90.00, and a low estimate of $63.00.

benzinga.com

31%
OFF

After Losing Over $16 Billion Of Market Capitalization

1 day from now

Nov 4, 2024 · These events drove the price of Edwards Lifesciences shares down $27.25 (-31%) on July 25, 2024, wiping out over $16 billion of shareholder value in a single day.

globenewswire.com

$1
OFF

Edwards Spends $1.2B On 2 Heart Device Firms, Extending Deal Streak

1 day from now

Jul 25, 2024 · Edwards Lifesciences said Wednesday it will pay about $1.2 billion to acquire a pair of cardiac device companies that will expand its lineup of structural heart offerings. The …

medtechdive.com

31%
OFF

Understanding The Edwards Lifesciences Securities Fraud Case

1 day from now

Oct 23, 2024 · How much did Edwards Lifesciences stock drop after the news? Following the guidance cut, Edwards Lifesciences stock dropped by 31%, going from $86.95 to $59.70 per …

investorshangout.com

$76.71
OFF

Assessing Edwards Lifesciences: Insights From 14 Financial Analysts

1 day from now

Jan 12, 2024 · Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $76.71, a high estimate of $85.00, and a low estimate of $57.00.

businessinsider.com

$311.58
OFF

The Analyst Verdict: Biogen In The Eyes Of 12 Experts

1 day from now

Jul 29, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $311.58, a high estimate of $342.00, and a low estimate of …

nasdaq.com

FAQs about The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts Coupon?

How do financial analysts perceive Edwards Lifesciences?

The perception of Edwards Lifesciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. ...

How do analysts react to Edwards Lifesciences?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. ...

How can I view Edwards Lifesciences's market performance?

To gain a panoramic view of Edwards Lifesciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table. Stay up to date on Edwards Lifesciences analyst ratings. ...

How do analysts evaluate Edwards Lifesciences (Els)?

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edwards Lifesciences compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Edwards Lifesciences's future value. ...

Who is Edwards Lifesciences?

Stay up to date on Edwards Lifesciences analyst ratings. Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. ...

How did Edwards Lifesciences perform over 3 months?

Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.5% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. ...